JW
Therapeutic Areas
Cassava Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Simufilam (PTI-125) | Alzheimer's Disease | Phase 3 |
| SavaDx | Alzheimer's Disease (Diagnostic) | Pre-clinical |
Leadership Team at Cassava Sciences
RB
Remi Barbier
President, Chief Executive Officer, and Chairman of the Board
EJ
Eric J. Schoen
Chief Financial Officer
DR
David R. Gwynn, J.D.
Senior Vice President, General Counsel, and Corporate Secretary
LA
Lindsay A. Burns, Ph.D.
Senior Vice President of Neuroscience
SR
Sanford Robertson
Director
RB
Richard Barry
Director
PJ
Patrick J. McEnany
Director